UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study

Brain (London, England : 1878), 2015-04, Vol.138 (Pt 4), p.963-973

2015

Volltextzugriff (PDF)

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease

Movement disorders, 2016-09, Vol.31 (9), p.1373-1380

2016

Volltextzugriff (PDF)

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease

Journal of Parkinson's disease, 2017-01, Vol.7 (4), p.629-634

2017

Volltextzugriff (PDF)

A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine

Neurology, 2004-07, Vol.63 (2), p.261-269

2004

Volltextzugriff (PDF)

Therapeutic innovation in Parkinson's disease: a 2020 update on disease-modifying approaches

Expert review of neurotherapeutics, 2020-10, Vol.20 (10), p.1047-1064

2020

Volltextzugriff (PDF)

Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease

Neuropharmacology, 2020-05, Vol.167, p.108006, Article 108006

2020

Volltextzugriff (PDF)

Effects of safinamide on the glutamatergic striatal network in experimental Parkinson’s disease

Neuropharmacology, 2020-06, Vol.170, p.108024, Article 108024

2020

Volltextzugriff (PDF)

The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model

Movement disorders, 2014-07, Vol.29 (8), p.1074-1079

2014

Volltextzugriff (PDF)

Food and Drug Administration Public Workshop Summary—Addressing Challenges in Inhaled Antifungal Drug Development

Clinical infectious diseases, 2024-06, Vol.78 (6), p.1564-1570

2024

Volltextzugriff (PDF)

Safinamide's potential in treating nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo

Experimental neurology, 2020-06, Vol.328, p.113287-113287, Article 113287

2020

Volltextzugriff (PDF)

M1867 Efficacy and Tolerability of ADX10059, a Negative Allosteric Modulator of mGluR5, On Gastro-Esophageal Reflux: A pH-Impedance Study in Healthy Subjects

Gastroenterology (New York, N.Y. 1943), 2009, Vol.136 (5), p.A-434-A-435

2009

Volltextzugriff (PDF)

Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol‐delivery form of lidocaine‐prilocaine for treating premature ejaculation

BJU international, 2007-02, Vol.99 (2), p.369-375

2007

Volltextzugriff (PDF)

Metabotropic glutamate receptor 5: a target for migraine therapy

Annals of clinical and translational neurology, 2016-08, Vol.3 (8), p.560-571

2016

Volltextzugriff (PDF)

Migraine Headache Recurrence: Relationship to Clinical, Pharmacological, and Pharmacokinetic Properties of Triptans

Headache, 2003-04, Vol.43 (4), p.376-388

2003

Volltextzugriff (PDF)

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease: Dipraglurant in Levodopa-Induced Dyskinesia

Movement disorders, 2016-09, Vol.31 (9), p.1373-1380

2016

Volltextzugriff (PDF)

268 A NOVEL APPROACH TO TREAT OVERACTIVE BLADDER BY POSITIVE MODULATION OF THE GABA-B RECEPTOR (GABA-BR) WITH ADX71441

The Journal of urology, 2012-04, Vol.187 (4), p.e109-e109

2012

Volltextzugriff (PDF)

Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe

Current medical research and opinion, 2004-09, Vol.20 (9), p.1465-1472

2004

Volltextzugriff (PDF)

Safety, Tolerability and Anti-Dyskinetic Efficacy of Dipraglurant, a Novel mGluR5 Negative Allosteric Modulator (NAM) in Parkinson's Disease (PD) Patients with Levodopa-Induced Dyskinesia (LID) (S23.004)

Neurology, 2013-02, Vol.80 (7_supplement)

2013

Volltextzugriff (PDF)

W1085 Clinical Efficacy and Tolerability of Monotherapy With ADX10059, a mGluR5 Negative Allosteric Modulator, for Symptom Control in Patients With Gastro-Esophageal Reflux Disease (GERD)

Gastroenterology (New York, N.Y. 1943), 2010, Vol.138 (5), p.S-648-S-648

2010

Volltextzugriff (PDF)

774 Effect of mGluR5 Inhibition with ADX10059, On Day and Night Time Reflux and Clinical Symptoms, in Patients with Gastro-Esophageal Reflux Disease (GERD): A Proof of Concept Study

Gastroenterology (New York, N.Y. 1943), 2009, Vol.136 (5), p.A-121-A-122

2009

Volltextzugriff (PDF)

Response From Geraud and Keywood

Headache, 2003-11, Vol.43 (10), p.1121-1121

2003

Volltextzugriff (PDF)

Efficacy and Tolerability of ADX10059, a mGluR5 Negative Allosteric Modulator, as Add on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux Disease (GERD)

Gastroenterology (New York, N.Y. 1943), 2011, Vol.140 (5), p.S-577-S-577

2011

Volltextzugriff (PDF)

Clinical Efficacy of Frovatriptan: Placebo-Controlled Studies

Headache, 2002-04, Vol.42 (s2), p.84-92

2002

Volltextzugriff (PDF)

935 Effect of mGluR5 Negative Allosteric Modulator (NAM) ADX10059, Monotherapy, on Reflux Events and Lower Esophageal Sphincter (LES) Function in Patients With Gastro-Esophageal Reflux Disease (GERD)

Gastroenterology (New York, N.Y. 1943), 2010, Vol.138 (5), p.S-135-S-135

2010

Volltextzugriff (PDF)

Dose Range-Finding Studies With Frovatriptan in the Acute Treatment of Migraine

Headache, 2002-04, Vol.42 (s2), p.74-83

2002

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Neurosciences & Neurology
(18)
Humans
(17)
Clinical Neurology
(14)
Male
(13)
Migraine Disorders - Drug Therapy
(11)
Double-Blind Method
(10)
Female
(10)
Migraine
(9)
Serotonin Receptor Agonists - Therapeutic Use
(9)
Adult
(8)
Biological And Medical Sciences
(8)
Medical Sciences
(8)
Middle Aged
(8)
Aged
(7)
Treatment Outcome
(7)
Neurology
(6)
Neurosciences
(6)
Tryptamines
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Headache
(16)
Gastroenterology
(5)
Movement Disorders
(3)
Neurology
(2)
Neuropharmacology
(2)
Annals Of Clinical And Translational Neurology
(1)
Bju International
(1)
Brain
(1)
Clinical Infectious Diseases
(1)
Current Medical Research And Opinion
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease

A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine

Therapeutic innovation in Parkinson's disease: a 2020 update on disease-modifying approaches

Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease

Effects of safinamide on the glutamatergic striatal network in experimental Parkinson’s disease

The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model

Food and Drug Administration Public Workshop Summary—Addressing Challenges in Inhaled Antifungal Drug Development

Safinamide's potential in treating nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo

M1867 Efficacy and Tolerability of ADX10059, a Negative Allosteric Modulator of mGluR5, On Gastro-Esophageal Reflux: A pH-Impedance Study in Healthy Subjects

Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol‐delivery form of lidocaine‐prilocaine for treating premature ejaculation

Metabotropic glutamate receptor 5: a target for migraine therapy

Migraine Headache Recurrence: Relationship to Clinical, Pharmacological, and Pharmacokinetic Properties of Triptans

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease: Dipraglurant in Levodopa-Induced Dyskinesia

268 A NOVEL APPROACH TO TREAT OVERACTIVE BLADDER BY POSITIVE MODULATION OF THE GABA-B RECEPTOR (GABA-BR) WITH ADX71441

Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe

Safety, Tolerability and Anti-Dyskinetic Efficacy of Dipraglurant, a Novel mGluR5 Negative Allosteric Modulator (NAM) in Parkinson's Disease (PD) Patients with Levodopa-Induced Dyskinesia (LID) (S23.004)

W1085 Clinical Efficacy and Tolerability of Monotherapy With ADX10059, a mGluR5 Negative Allosteric Modulator, for Symptom Control in Patients With Gastro-Esophageal Reflux Disease (GERD)

774 Effect of mGluR5 Inhibition with ADX10059, On Day and Night Time Reflux and Clinical Symptoms, in Patients with Gastro-Esophageal Reflux Disease (GERD): A Proof of Concept Study

Response From Geraud and Keywood

Efficacy and Tolerability of ADX10059, a mGluR5 Negative Allosteric Modulator, as Add on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux Disease (GERD)

Clinical Efficacy of Frovatriptan: Placebo-Controlled Studies

935 Effect of mGluR5 Negative Allosteric Modulator (NAM) ADX10059, Monotherapy, on Reflux Events and Lower Esophageal Sphincter (LES) Function in Patients With Gastro-Esophageal Reflux Disease (GERD)

Dose Range-Finding Studies With Frovatriptan in the Acute Treatment of Migraine

Suchergebnisse filtern